Субъективный компонент терапевтического действия психофармакологических препаратов
Рекомендуемое оформление библиографической ссылки:
Метлина М.В., Дорофеева О.А. Субъективный компонент терапевтического действия психофармакологических препаратов // Российский психиатрический журнал. 2022. №5. С. 39-50.
В научном обзоре с целью расширения представлений о субъективном компоненте терапевтического действия психофармакологических препаратов представлены обобщающие данные о феномене и структуре субъективного фактора, физиологических и нейробиологических основах его формирования. Показана его связь с объективными характеристиками фармакологического действия, а также возможности практического применения субъективной оценки в клинической практике. Приведённые данные свидетельствуют об актуальности и высокой значимости субъективного фактора в реализации действия психофармакологических средств. Исследования в этой области позволят выявить дополнительные индивидуальные эффекты у психофармакологических препаратов и особенности их клинико-фармакологического действия, что расширит возможности персонифицированного подхода в терапии психических расстройств.
Ключевые слова субъективная оценка; терапевтическое действие; психофармакологические препараты; интероцептивные эффекты; плацебо-эффект; эффективность терапии; персонализированный подход
1. Louza Neto MR, Müller-Spahn F, Rüther E, Scherer J. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry. 1988;21(5):226–31. DOI: https://doi.org/10.1055/s-2007-1014680 2. Benedetti F, Carlino E, Pollo A. How placebos change the patient’s brain. Neuropsychopharmacology. 2011;36(1):339–54. DOI: https://doi.org/10.1038/npp.2010.81 3. Awad AG. “The patient”: at the center of patient-reported outcomes. Expert Rev Pharmacoeconomics Outcomes Res. 2015;15(5):729–31. DOI: https://doi.org/10.1586/14737167.2015.1077118 4. Lektorskii VA. Epistemologiya klassicheskaya i neklassicheskaya. Moscow; 2001. 256 p. (In Russ.) 5. Sutuzhko VV. [Struktura, printsipy i klassifikatsiya ponyatiya “otsenka”]. Epistemologiya i filosofiya nauki [Epistemologiya i filosofiya nauki]. 2008;XVIII(4):108–24. (In Russ.) 6. Tkhostov ASh. Psikhologiya telesnosti. Moscow; 2002. 177 p. (In Russ.) 7. Kemp AH, Gordon E, Rush AJ, Williams LM. Improving the prediction of treatment response in depression: Integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectrums. 2008;12(13):1066–86. DOI: https://doi.org/10.1017/s1092852900017120 8. Lacro JP, Dunn LB, Dolder CR, Leckband SG. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909. DOI: https://doi.org/10.4088/jcp.v63n1007 9. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23. DOI: https://doi.org/10.1056/NEJMoa051688 10. Banshchikov FR. [Komplaens v psikhiatrii: real'nost' i perspektivy]. Obozrenie psikhiatrii i med.psikhologii [Obozrenie psikhiatrii i med.psikhologii]. 2006;4:9–11. (In Russ.) 11. Velligan DI, Sajatovic M, Hatch A., Kramata P. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–68. DOI: https://doi.org/10.2147/PPA.S124658 12. Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorder. Psychiatry Res. 2015;225(1–2):14–30. DOI: https://doi.org/10.1016/j.psychres.2014.11.002 13. Mora MS, Nestoriuc Y, Rief W. Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc L B Biol Sci. 2011;366:1879–88. DOI: https://doi.org/10.1098/rstb.2010.0394 14. Chakhava VO, Chernykh OV. [Platsebo-effekt i problema terapii generalizovannogo trevozhnogo rasstroistva (obzor literatury)]. Psikhiatriya i psikhofarmakoterapiya im. PB Gannushkina [Psikhiatriya i psikhofarmakoterapiya im. PB Gannushkina]. 2005;2:69–71. (In Russ.) 15. Lapin IP. Platsebo i terapiya. Saint-Petersburg; 2000. 223 p. (In Russ.) 16. Van Putten TP, May RA. Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point. Arch. Gen Psychiatry. 1978;35(4):477–80. DOI: https://doi.org/10.1001/archpsyc.1978.01770280087009 17. Mohamed S, Rosenheck R, McEvoy J, et al. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull. 2009;35(2):336–46. DOI: https://doi.org/10.1093/schbul/sbn067 18. Mauriño JJ, Sanjúan JM, Haro T. Díez Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia. Patient Prefer Adherence. 2011;5:471–4. DOI: https://doi.org/10.2147/PPA.S24479 19. Vassileva IV, Milanova VK. Attitudes toward antipsychotic medication, insight and psychopathology in outpatients with schizophrenia. Folia Med (Plovdiv). 2012;54(4):62–8. DOI: https://doi.org/10.2478/v10153-012-0007-3 20. Murawiec S, Boutros NN. Correlation between early subjective response to antipsychotics and the number of hospitalizations and hospitalization days in a period of 10–11 years in schizophrenia patients. Neuropsychobiology. 2012;66(2):120–5. DOI: https://doi.org/10.1159/000339092 21. Neznamov GG, Syunyakov SA, Bochkarev VK, Teleshova ES. Sub"ektivnaya otsenka bol'nymi deistviya testovoi dozy anksiolitikov kak prediktor effektivnosti terapii. In: Seredenin SB, editor. Fenazepam: 25 let v meditsinskoi praktike. Moscow; 2007. p. 273–7. (In Russ.) 22. Hunter R, Cameron R, Norrie J. Using patient-reported outcomes in schizophrenia: the scottish schizophrenia outcomes study. Psychiatr Serv. 2009;60(2):240–5. DOI: https://doi.org/10.1176/ps.2009.60.2.240 23. Reutova MA, Syunyakov SA, Syunyakov TS, Neznamov GG. [Anksiolitik afobazol® – sub"ektivnaya otsenka deistviya preparata bol'nymi s trevozhno-astenicheskimi rasstroistvami]. Eksp Klin Farmakol. 2010;73(9):6–12. (In Russ.) DOI: https://doi.org/10.30906/0869-2092-2010-73-9-6-12; PMID: 21086645 24. Goodman C, Knoll G, Isakov V, Silver H. Negative attitude towards medication is associated with working memory impairment in schizophrenia patients. Int Clin Psychopharmacol. 2005;20(2):93–6. DOI: https://doi.org/10.1097/00004850-200503000-00005 25. Neznamov GG, Bochkarev VK. [Sub"ektivnaya otsenka bol'nymi s trevozhnymi rasstroistvami deistviya odnokratnykh testovykh doz fenazepama i platsebo: svyaz' s ob"ektivnymi farmakoelektroentsefalograficheskimi kharakteristikami]. Zh Nevrol Psikhiatr Im SS Korsakova. 2018;118(9):53–60. (In Russ.) DOI: https://doi.org/10.17116/jnevro201811809153 26. Neznamov GG, Syunyakov SA, Syunyakov TS, et al. [Zavisimost' sub"ektivnoi otsenki deistviya anksiolitikov – fenazepama i afobazola ot individual'no-tipologicheskikh osobennostei bol'nykh s trevozhnymi rasstroistvami]. Psikhiatriya i psikhofarmakoterapiya im. PB Gannushkina [Psikhiatriya i psikhofarmakoterapiya im. PB Gannushkina]. 2014;16(5):24–9. (In Russ.) 27. Dijk FA, Schirmbeck F, de Haan L. A longitudinal analysis of the effects of neuroticism and extraversion on subjective well-being in patients with schizophrenia. Psychiatry Res. 2018;259:538–44. DOI: https://doi.org/10.1016/j.psychres.2017.11.011 28. Axelsson M, Brink E, Lundgren J. The influence of personality traits on reported adherence to medication in individuals with chronic disease: an epidemiological study in west sweden. PLoS One. 2011;6(3):18241. DOI: https://doi.org/10.1371/journal.pone.0018241 29. Emilsson M, Gustafsson P, Öhnström G, Marteinsdottir I. Impact of personality on adherence to and beliefs about ADHD medication, and perceptions of ADHD in adolescents. BMC Psychiatry. 2020;20(1):139. DOI: https://doi.org/10.1186/s12888-020-02543-х 30. Sprangers MA, Bartels M, Veenhoven R, et al. Which patient will feel down, which will be happy? The need to study the genetic disposition of emotional states. Qual Life Res. 2010;19(10):1429–37. DOI: https://doi.org/10.1007/s11136-010-9652-2 31. Kamei K, Terao T, Katayama Y, Hoaki N. Affective temperaments and psychotropic adherence. J Affect Disord. 2013;150(3):1142–7. DOI: https://doi.org/10.1016/j.jad.2013.05.064 32. Borodin VI. Perenosimost' lecheniya u bol'nykh s depressivnymi rasstroistvami (kompleksnyi analiz). [PhD thesis]. [Moscow (Russia)]: Moskovskiy nauchno-issledovatelskiy institut psikhiatrii [Moscow Research Institute of Psychiatry]; 2009. 35 p. (In Russ.) 33. Bahrini L, Damak R., Cheour M. The role of the affective temperament in the treatment adherence in psychiatry. Pan Afr Med J. 2016;25(2):1–7. DOI: https://doi.org/10.11604/pamj.2016.25.2.8400 34. Liraud F, Verdoux H. Association between temperamental characteristics and medication adherence in subjects presenting with psychotic or mood disorders. Psychiatry Res. 2001;102(1):91–5. DOI: https://doi.org/10.1016/s0165-1781(01)00240-2 35. Fischel T, Krivoy A, Kotlarov M, et al. The interaction of subjective experience and attitudes towards specific antipsychotic-related adverse effects in schizophrenia patients. Eur Psychiatry. 2013;28(6):340–3. DOI: https://doi.org/10.1016/j.eurpsy.2012.06.005 36. Hatano M, Kamei H, Kato A, et al. Assessment of the latent adverse events of antipsychotic treatment using a subjective questionnaire in Japanese patients with schizophrenia. Clin Psychopharmacol Neurosci. 2017;15(2):132–7. DOI: https://doi.org/10.9758/cpn.2017.15.2.132 37. Kassew T, Demilew D, Birhanu A, et al. Attitude towards antipsychotic medications in patients diagnosed with schizophrenia: a cross-sectional study at amanuel mental specialized hospital, Addis Ababa, Ethiopia. Schizophr Res Treat. 2019;2019:1–9. DOI: https://doi.org/10.1155/2019/5094017 38. Akhapkin RV. [Ob"ektivnaya i sub"ektivnaya otsenki nezhelatel'nykh yavlenii pri izuchenii sravnitel'noi perenosimosti antidepressantov]. Psikhiatriya i psikhofarmakoterapiya im. PB Gannushkina [Psikhiatriya i psikhofarmakoterapiya im. PB Gannushkina]. 2003;3:103–6. (In Russ.) 39. Tham XC, Xie H, Chng CML, et al. Factors Affecting Medication Adherence Among Adults with Schizophrenia: A Literature Review. Arch Psychiat Nurs. 2016;30(6):797–809. DOI: https://doi.org/10.1016/j.apnu.2016.07.007 40. Lincoln TM, Jung E, Wiesjahn M, et al. The impact of negative treatment experiences on persistent refusal of antipsychotics. Compr Psychiatry. 2016;70:165–73. DOI: https://doi.org/10.1016/j.comppsych.2016.07.009 41. Lysaker PH, Pattison ML, Leonhardt BL, Phelps S. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry. 2018;17(1):12–23. DOI: https://doi.org/10.1002/wps.20508 42. Ritsner M, Ponizovsky A, Endicott J, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol. 2002;12(1):31–8. DOI: https://doi.org/10.1016/s0924-977x(01)00128-6 43. Schroeder K, Huber CG, Jelinek L, Moritz S. Subjective well-being, but not subjective mental functioning shows positive associations with neuropsychological performance in schizophrenia-spectrum disorders. Compr Psychiatry. 2013;54(7):824–30. DOI: https://doi.org/10.1016/j.comppsych.2013.02.008 44. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(3):133–8. PMID: 8866775 45. Lambert M, Schimmelmann BG, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs – concepts, measurement and clinical relevance. Pharmacopsychiatry. 2003;36(3):181–90. DOI: https://doi.org/10.1055/s-2003-45128 46. Neznamov GG, Metlina MV, Bogdanova NI, et al. [Sub"ektivnaya otsenka bol'nymi deistviya anksiolitikov: zavisimost' ot struktury trevozhnykh rasstroistv]. Psikhiatriya i psikhofarmakoterapiya im. PB Gannushkina [Psikhiatriya i psikhofarmakoterapiya im. PB Gannushkina]. 2017;19(3):10–8. (In Russ.) 47. Lindström LH. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand Suppl. 1994;380:74–6. DOI: https://doi.org/10.1111/j.1600-0447.1994.tb05837.x 48. May PRA, Van Putten T, Jenden DJ, et al. Prognosis in schizophrenia: individual differences in psychological response to a test dose of antipsychotic drug and their relationship to blood and saliva levels and treatment outcome. Compr Psychiatry. 1981;22(2):147–52. DOI: https://doi.org/10.1016/0010-440x(81)90062-6 49. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19(3):609–18. DOI: https://doi.org/10.1093/schbul/19.3.609 50. Voruganti LN, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia-findings from an in vivo SPECT study. Schizophr Res. 2006;88(1–3):179–86. DOI: https://doi.org/10.1016/j.schres.2006.07.012 51. Voruganti L, Slomka P, Zabel P, et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia, the correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacology. 2001;25:642–50. DOI: https://doi.org/10.1016/S0893-133X(01)00263-9 52. Schultz W, Apicella P, Scarnati E. Neuronal activity in monkey ventral striatum related to the expectation of reward. J Neurosci. 1992;12(12):4595–610. DOI: https://doi.org/10.1523/JNEUROSCI.12-12-04595.1992 53. Karamatskos E, Mulert C, Lambert M, Naber D. Subjective well-being of patients with schizophrenia as a target of drug treatment. Curr Pharm Biotechnol. 2012;13(8):1490–9. DOI: https://doi.org/10.2174/138920112800784862 54. De Haan L, Lavalaye J, Van Bruggen M, et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry. 2004;49(5):290–6. DOI: https://doi.org/10.1177/070674370404900503 55. Porter JH, Prus AJ, Overton DA. Drug Discrimination: Historical Origins, Important Concepts, and Principles. Curr Top Behav Neurosci. 2018;39:3–26. DOI: https://doi.org/10.1007/7854_2018_40 56. Naqvi NH, Bechara A. The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-making. Brain Struct Funct. 2010;214(5–6):435–50. DOI: https://doi.org/10.1007/s00429-010-0268-7 57. Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci. 2002;3(8):655–66. DOI: https://doi.org/10.1038/nrn894 58. Tkhostov ASh, Nelyubina AS. [Obydennye predstavleniya kak faktor, oposreduyushchii povedenie v situatsii bolezni]. Vestn. Tomsk. un-ta. Seriya: Psikhologiya [Vestn. Tomsk. un-ta. Seriya: Psikhologiya]. 2008;317:243–6. (In Russ.) 59. Artem'eva EYu. Psikhologiya sub"ektivnoi semantiki. Moscow; 2007. 126 p. (In Russ.) 60. Holtzman SG, Locke KW. Neural mechanisms of drug stimuli: experimental approaches. Psychopharmacol Ser. 1988;4:138–53. PMID: 3293038 61. Dunn BD, Stefanovitch I, Evans D, et al. Can you feel the beat? Interoceptive awareness is an interactive function of anxiety and depression specific symptom dimensions. Behav Res Ther. 2010;48(10):1133–8. DOI: https://doi.org/10.1016/j.brat.2010.07.006 62. Weissman A. The discriminability of apsirin in arthritic and nonarthritic rats. Pharmacol Biochem Behav. 1976;5(5):583–6. DOI: https://doi.org/10.1016/0091-3057(76)90273-2 63. Paulus MP, Stewart JL. Interoception and drug addiction. Neuropharmacology. 2014;76:342–50. DOI: https://doi.org/10.1016/j.neuropharm.2013.07.002 64. Pollatos O, Traut-Mattausch E, Schandry R. Differential effects of anxiety and depression on interoceptive accuracy. Depress Anxiety. 2009;26(2):167–73. DOI: https://doi.org/10.1002/da.20504 65. Benedetti F, Piedimonte A. The neurobiological underpinnings of placebo and nocebo effects. Semin Arthritis Rheum. 2019;3S:18–21. DOI: https://doi.org/10.1016/j.semarthrit.2019.09.015 66. Colloca LMF, Miller FG. How placebo responses are formed: a learning perspective. Philos Trans R Soc L B Biol Sci. 2011;366(1572):1859–69. DOI: https://doi.org/10.1098/rstb.2010.0398 67. Colagiuri B, Schenk LA, Kessler MD, et al. The Placebo effect: from concepts to genes. Neuroscience. 2015;307:171–90. DOI: https://doi.org/10.1016/j.neuroscience.2015.08.017 68. Brown WA. Expectation, the placebo effect and the response to treatment. R I Med J. 2015;98(5):19–21. PMID: 25938400 69. Kam-Hansen S, Jakubowski M, Kelley JM, et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014;6(218):218ra5. DOI: https://doi.org/10.1126/scitranslmed.3006175 70. Peciña M, Azhar H, Love TM, et al. Personality trait predictors of placebo analgesia and neurobiological correlates. Neuropsychopharmacology. 2013;38(4):639–46. DOI: https://doi.org/10.1038/npp.2012.227 71. Zhang W, Qin S, Guo J. A follow-up fMRI study of a transferable placebo anxiolytic effect. Psychophysiology. 2011;48:1119–28. DOI: https://doi.org/10.1111/j.1469-8986.2011.01178.x 72. Faria V, Ahs F, Appel L, et al. Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder. Int J Neuropsychopharmacol. 2014;17:1149–57. DOI: https://doi.org/10.1017/S1461145714000352 73. Neznamov GG, Bochkarev VK. Sub"ektivnaya otsenka bol'nymi s trevozhnymi rasstroistvami deistviya odnokratnykh testovykh doz fenazepama i platsebo : svyaz' s ob"ektivnymi farmakoelektroentsefalograficheskimi kharakteristikami. Zh Nevrol Psikhiatr Im SS Korsakova. 2018;118(9):53–60. (In Russ.) DOI: https://doi.org/10.17116/jnevro201811809153 74. Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159(5):728–37. DOI: https://doi.org/10.1176/appi.ajp.159.5.728 75. Leuchter AF, Cook IA, Witte EA, et al. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002;159(1):122–9. DOI: https://doi.org/10.1016/j.jpsychires.2009.06.006 76. Nestoriuc Y, Orav EJ, Liang MH, Horne R. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res. 2010;62:791–9. DOI: https://doi.org/10.1002/acr.20160 77. Lovick TA. Pro-nociceptive action of cholecystokinin in the periaqueductal grey: a role in neuropathic and anxiety-induced hyperalgesic states. Neurosci Biobehav Rev. 2008;32:852–62. DOI: https://doi.org/10.1016/j.neubiorev.2008.01.003 78. Keltner JR, Furst A, Fan C, et al. Isolating the modulatory effect of expectation on pain transmission: a functional magnetic resonance imaging study. J Neurosci. 2006;26:4437–43. DOI: https://doi.org/10.1523/JNEUROSCI.4463-05.2006 79. Corfmat J, Januel D, Braha S, Moulier V. The placebo effect: general information and specificities in psychiatry (depression and schizophrenia). Encephale. 2012;38(1):50–7. DOI: https://doi.org/10.1016/j.encep.2011.01.010 80. Schimmelmann BG, Schacht M, Perro C, Lambert M. Die initial dysphorische reaktion (IDR) auf die ersteinnahme von neuroleptika. Nervenarzt. 2004;75(1):36–43. DOI: https://doi.org/10.1007/s00115-003-1544-z 81. Lehmann E. The dose-effect relationship of 0.5, 1.0 and 1.5 mg fluspirilene on anxious patients. Neuropsychobiology. 1989;21(4):197–204. DOI: https://doi.org/10.1016/0278-5846(92)90066-n 82. Naber D, Kollack-Walker S, Chen J, et al. Predicting a “combined treatment outcome” in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being. Pharmacopsychiatry. 2013;46(3):114–9. DOI: https://doi.org/10.1055/s-0032-1331703 83. Schennach-Wolff R, Jäger M, Obermeier M, et al. Quality of life and subjective well-being in schizophrenia and 738, schizophrenia spectrum disorders: valid predictors of symptomatic response and remission? World J Biol Psychiatry. 2010;11:729–38. DOI: https://doi.org/10.3109/15622971003690289 84. Möller HJ. Outcome criteria in antidepressant drug trials: self-rating versus observer-rating scales. Pharmacopsychiatry. 1991;24(3):71–5. DOI: https://doi.org/10.1055/s-2007-1014442 85. Priebe S, Bröker M. Initial response to active drug and placebo predicts outcome of antidepressant treatment. Eur Psychiatry. 1997;12(1):28–33. DOI: https://doi.org/10.1016/S0924-9338(97)86376-6 86. Brain C, Sameby B, Allerby K, et al. Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia. Eur Neuropsychopharmacol. 2014;24(2):215–22. DOI: https://doi.org/10.1016/j.euroneuro.2013.11.013 87. Widschwendter CG, Kemmler G, Rettenbacher MA, et al. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. BMC Psychiatry. 2018;18(1):1–9. DOI: https://doi.org/10.1186/s12888-018-1791-y 88. De las Cuevas C, Peñate W, Sanz EJ. Risk factors for non-adherence to antidepressant treatment in patients with mood disorders. Eur J Clin Pharmacol. 2014;70(1):89–98. DOI: https://doi.org/10.1007/s00228-013-1582-9 89. Mattila T, Koeter M, Wohlfarth T. The impact of second generation antipsychotics on insight in schizophrenia: results from 14 randomized, placebo controlled trials. Eur Neuropsychopharmacol. 2017;27:82–6. DOI: https://doi.org/10.1016/j.euroneuro.2016.10.004 90. Moran K, Priebe S. Better quality of life in patients offered financial incentives for taking anti-psychotic medication: Linked to improved adherence or more money? Qual Life Res. 2016;25(8):1897–902. DOI: https://doi.org/10.1007/s11136-016-1238-1 91. Abdel-Baki A, Ouellet-Plamondon C, Мalla A. Pharmacotherapy challenges in patients with first-episode psychosis. J Affect Disord. 2012;138:3–14. DOI: https://doi.org/10.1016/j.jad.2012.02.029 92. Serra-Blasco M, Torres IJ, Vicent-Gil M, et al. Discrepancy between objective and subjective cognition in major depressive disorder. Eur Neuropsychopharmacol. 2019;29(1):46–56. DOI: https://doi.org/10.1016/j.euroneuro.2018.11.1104 93. Reynolds AR, Bolin BL, Stoops WW, Rush CR. Relationship between drug discrimination and ratings of subjective effects: implications for assessing and understanding the abuse potential of D-amphetamine in humans. Behav Pharmacol. 2013;24(5-6):523– 32. DOI: https://doi.org/10.1097/FBP.0b013e328364505f
DOI: http://dx.doi.org/10.47877/1560-957Х-2022-10504
Метрики статей
Metrics powered by PLOS ALM